As a general rule, ribosomally synthesized polypeptides contain amino acids only in the L-isoform in an order dictated by the coding DNA͞RNA. Two of a total of only four examples of L to D conversions in prokaryotic systems occur in posttranslationally modified antimicrobial peptides called lantibiotics. In both examples (lactocin S and lacticin 3147), ribosomally encoded L-serines are enzymatically converted to D-alanines, giving rise to an apparent mistranslation of serine codons to alanine residues. It has been suggested that this conversion results from a two-step reaction initiated by a lantibiotic synthetase converting the gene-encoded L-serine to dehydroalanine (dha). By using lacticin 3147 as a model system, we report the identification of an enzyme, LtnJ, that is responsible for the conversion of dha to D-alanine. Deletion of this enzyme results in the residues remaining as dha intermediates, leading to a dramatic reduction in the antimicrobial activity of the producing strain. The importance of the chirality of the three D-alanines present in lacticin 3147 was confirmed when these residues were systematically substituted by L-alanines. In addition, substitution with L-threonine (ultimately modified to dehydrobutyrine), glycine, or L-valine also resulted in diminished peptide production and͞or relative activity, the extent of which depended on the chirality of the newly incorporated amino acid(s).
T
he presence of D-amino acids in ribosomally synthesized peptides was first observed in dermorphins, peptides found in the skin secretions of species of a subfamily of South American tree frogs, Phyllomedusinae. Subsequently, D-amino acids have been identified in a number of other ribosomally synthesized peptides of eukaryotic origin (1, 2) . -Agatoxin IVb and bombinin H, produced by the funnel-web spider and the skin secretions of the frog Bombina variegata, respectively, represent the only instances in which the responsible enzymes, both peptide epimerases, have been identified (1, 2) . For -agatoxin IVb the relevant L-serine to D-serine conversion is thought to involve a deprotonation͞reprotonation reaction (3) . The presence of D-amino acids in many of these peptides is crucial, as demonstrated by the creation of synthetic analogues with Lrather than D-amino acids at the relevant locations, which are devoid of activity (4) . The artificial incorporation of D-amino acids can also be beneficial. For example, a growing number of synthetic peptides͞peptide libraries containing D-amino acids have been assembled to capitalize on the ability of such residues to provide improved protease stability [enhanced pharmokinetic profile (5-7)], alter tertiary structure (new structural elements can be assembled that cannot be built solely from L-amino acids), and affect the activity of bioactive peptides [enhanced antibacterial activity with concomitant reduction in cell cytotoxicity (5, 6, (8) (9) (10) (11) ].
In prokaryotic systems, there are only a few examples of L-to D-amino acid conversions. It has recently been established that the gassericin A and reutericin 6 class II bacteriocins possess D-alanines, apparently arising from L-alanine to D-alanine conversion (12) . For quite some time, however, the presence of D-alanines in lacticin 3147 and lactocin S (13) (14) (15) , members of a group of highly posttranslationally modified antimicrobial peptides called lantibiotics (class I bacteriocins), has been the subject of much interest because the chirality and the identity of the relevant amino acids are altered. Lacticin 3147 is a twocomponent lantibiotic produced by Lactococcus lactis, which is active at low concentrations against a wide range of Grampositive organisms, including a number of human pathogenic bacteria, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci (16) . Lacticin 3147 is representative of an emerging subclass of lantibiotics, which also includes the enterococcal cytolytic toxin cytolysin (17) that functions through the combined activity of two lanthioninecontaining peptides. The two-component lacticin peptides, LtnA1 and LtnA2, act in concert to target the cell envelope of Gram-positive bacteria and to form pores in the membrane, leading to rapid cell death (18) . The NMR structures of both peptides has been recently elucidated (15) and confirm the extensive posttranslational modifications typical of the lantibiotic class of antimicrobial peptides (Fig. 1) . Of the 59 amino acids, 22 (6 serines, 9 threonines, and 7 cysteines) present in the ribosomally synthesized propeptides are posttranslationally modified and no longer represent the standard 20 amino acids commonly found in ribosomally synthesized peptides. In particular, four threonines and three serines are dehydrated by a specific enzyme termed a lantibiotic synthetase [each prepeptide has a dedicated lantibiotic synthetase, LtnM1 for LtnA1 and LtnM2 for LtnA2 (19) ] to form four dehydrobutyrines (dhb) and three dehydroalanines (dha). These dehydroamino acids interact with a neighboring cysteine to form seven lanthionine bridges typical of these antimicrobials (four in LtnA1 and three in LtnA2; see Fig. 1 ). Of the remaining threonines, three are unmodified and five are dehydrated to dhb and are unable to form lanthionine bridges because no cysteine partners are available. After cleavage of the leader during export, the Nterminal dhb of LtnA2 subsequently undergoes a spontaneous deamination to form 2-oxybutyrol. It is the fate of the remaining three serines (LtnA1 S7 and LtnA2 S9,12 ) that is most unusual, because neither serines nor dha are found at the corresponding locations in the mature peptides. Instead, the residues identified at these positions in the active peptides are alanines, and chiral phase analysis has confirmed that they are in the D-isoform (14, 15) . When considering the production of D-alanines in lactocin S, Skaugen et al. (13) proposed a model based on the ␣-epimer-ization sequence (20) and on the stereoinversion involved in lanthionine formation (21) . These authors speculated that a two-step process takes place: first, the conversion of an L-serine residue to dha (which is nonchiral) by the dedicated lantibiotic synthetase and, second, a stereospecific enzymatic hydrogenation event to form D-alanine (Fig. 1) . However, no enzyme has as yet been identified as a candidate to catalyze this second step.
Here we identify the enzyme responsible for this conversion in lacticin 3147 and demonstrate that mutagenesis of this enzyme dramatically reduces the bioactivity of the antimicrobial. Furthermore, we investigate whether any alternate residues can efficiently compensate for the removal of the D-alanines from these peptides. (25) , respectively. L. lactis strains were grown in M17 broth supplemented with 0.5% glucose (GM17) or GM17 agar at 30°C unless stated otherwise. L. lactis were grown in modified tryptone-yeast broth (14) for the purpose of peptide purification. E. coli was grown in LuriaBertani broth or agar at 37°C. Erythromycin and chloramphenicol were used at 5 g͞ml for L. lactis at 150 and 10 g͞ml, respectively, for E. coli. When present, 5-bromo-4-chloro-3-indolyl-␤-D-galactosidase was used at a concentration of 40 g͞ml.
Materials and Methods
Deletion and Expression of ltnJ. Deletion of ltnJ was carried out by using a combination of splicing by overlap extension PCR (26) and a double-crossover recombination event as described in ref. 22 to create a ⌬ltnJ mutant, from which 1,056 nucleotides has been deleted. To express ltnJ, a DNA product generated with PCR primers 5 and 6 was digested with XbaI and HinDIII; ligated with similarly digested pNZ44, an E. coli-L. lactis shuttle vector with a constitutive P44 promoter (25) ; and electroporated into E. coli DH5␣ to generate a transcriptional fusion between the constitutive lactococcal promoter P44 and ltnJ. Plasmid was isolated, sequenced to ensure integrity, and electroporated into ⌬ltnJ to create ⌬ltnJpNZ44ltnJ. The control strain ⌬ltnJpNZ44 was also created.
Residue-Specific Mutagenesis. Two methods were used for sitedirected mutagenesis. The first method was derived from the splicing by overlap extension PCR technique described above in that two PCR products were again spliced, except that, in these instances, nucleotide changes were incorporated into overlapping regions of the two products to change codons in a sitespecific manner (nucleotides altered for this purpose are underlined in Table 2 , which is published as supporting information on the PNAS web site). For example, to generate pOri-ltnA1S7A, primer pairs 7-11 and 12-8 were used during a first-round PCR. A second-round PCR using primers 7 and 8 resulted in the creation of a spliced product with a TCG to GCA alteration. The spliced product was digested with PstI and EcoRI, cloned into pORI280, and introduced into EC101. This approach was also taken to create pOri-ltnA2S9A (primers 9, 13, 14, and 10) , pOri-ltnA2S12A (primers 9, 16, 17, and 10), and pOriltnA2S9,12A (primers 9, 19, 20, and 10).
Alternatively QuikChange XL site-directed mutagenesis (Stratagene) was adapted to incorporate changes into ltnA1 and ltnA2. To generate a template for mutagenesis, a 998-bp region encompassing the ltnA1 and A2 genes and flanking regions was PCR-amplified (primers 7 and 10). This fragment was inserted into pORI280 and introduced into EC101, and its fidelity was checked by DNA sequencing. This plasmid was then reisolated and used as a template for site-directed mutagenesis using the QuikChange XL site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions with the exception that EC101 was used as the E. coli host because of the RepA Ϫ nature of pORI280. In this way, the following pORI280-ltnA1A2 derivatives were made: pOri-ltnA1S7T (primer pair [21] [22] , pOri-ltnA1S7G (primer pair 24-25), pOri-ltnA1S7V (primer pair 27-28), pOri-ltnA2S9T (primer pair 30-31), pOri-ltnA2S9G (primer pair 33-34), pOri-ltnA2S9V (primer pair 36-37), pOriltnA2S9,12T (primer pair 39-40), pOri-ltnA2S9,12G (primer pair 42-43), and pOri-ltnA2S9,12V (primer pair 45-46). Screening of candidate EC101 transformants was facilitated by the use of check primers 23, 26, 29, 32, 35, 38, 41, 44 , and 47, respectively, in conjunction with either primer 7 or 8, depending on the orientation of the check primer. In all cases successful mutagenesis was confirmed by DNA sequencing. Regardless of how the altered ltnA1 and ltnA2 genes were introduced into pORI280, the next step in the procedure involved the electroporation (27, 28) of the pORI280-ltnA1A2 derivative into MGMRpVe or MGMR⌬ltnA1pVe and the ultimate incorporation of the genes by double-crossover homologous recombination into pMRC01 or pMRC01⌬ltnA1 in place of the corresponding region After an initial screen of candidate mutants using check primers, DNA sequencing was again used to confirm successful mutagenesis.
Purification of the LtnA1 and LtnA2
Peptides. An overnight culture of the strain of interest was inoculated into 1 liter of modified tryptone-yeast broth (1% inoculum). The inoculated medium was incubated overnight at 30°C, and the cells were harvested by centrifugation at 7,000 ϫ g for 20 min and resuspended in 250 ml of 70% propan-2-ol, pH 2.0 (adjusted to pH 2.0 by addition of concentrated HCl). After being stirred for 4 h at 4°C, the cell debris was removed by centrifugation, and the bacteriocincontaining supernatant was reduced to Ϸ60 ml by removing propan-2-ol via rotary evaporation. The resultant preparation was applied to a 10-g (60-ml volume) Bond Elut C 18 column (Varian, Harbor City, CA) preequilibrated with methanol and water. The column was subsequently washed with 120 ml of 30% ethanol, and inhibitory activity was eluted with 100 ml of 70% propan-2-ol, pH 2. From the 100-ml, bacteriocin-containing eluate, 10 ml or 20 ml (depending on peak size) was concentrated to a volume of 1 ml through the removal of propan-2-ol by rotary evaporation. Aliquots of 700 l were then applied to a 250-ϫ 10.0-mm, Jupiter Proteo C 12 RP-HPLC column (particle size, 4 m; pore size, 90 Å; Phenomenex, Cheshire, U.K.) previously equilibrated with 25% propan-2-ol͞0.1% trifluoroacetric acid (TFA). The column was subsequently developed in a gradient of 30% propan-2-ol containing 0.1% TFA to 60% propan-2-ol containing 0.1% TFA from 4 to 40 min at a flow rate of 1.2 ml͞min. Peak areas were calculated with Shimadzu class VP software. Individual (post-HPLC fraction collection) peptides were subjected to mass analysis (MALDI-TOF MS) with an AXIMA-CFR plus mass spectrometer (Shimadzu).
Bioassays for Antimicrobial Assay. Bioactivity was assessed by well-diffusion assays unless stated otherwise. For this purpose, molten agar was cooled to 48°C and seeded with L. lactis HP (Ϸ10 6 fresh overnight-grown cells per ml). The inoculated medium was dispensed into sterile Petri plates in 20-ml volumes, allowed to solidify, and dried. Wells (4.6 mm in diameter) were then bored in the seeded agar plates, and 50-l volumes of the liquid to be assayed were dispensed into these wells. To assay the antimicrobial capacity of overnight cultures (bioactivity) of MGMR and bioengineered derivatives, the cultures were centrifuged and the cell-free supernatant was removed and serially diluted in one-quarter-strength Ringer's solution before being added to wells. To determine the relative activity of HPLCpurified peptides, entire peaks were purified and the peptide concentrations were normalized through dilution with 48.3% (LtnA1) or 54.8% (LtnA2) propan-2-ol, i.e., the concentrations at which the respective peptides elute. The degree to which dilution occurred was calculated on the basis that a 1:1 ratio exists between lacticin peptide concentrations and peak size as determined at 214 nm (data not shown). Each peptide was then subjected to serial two-fold dilutions before being mixed in a 1:1:2 ratio with purified wild-type companion peptide (Ͼ200 nM) and one-quarter-strength Ringer's solution, respectively, before being added to the wells. In both cases, plates were incubated at 30°C overnight, and growth inhibition relative to the relevant wild-type control was determined on the basis of the highest dilution that gave a definite zone of inhibition. For deferred antagonism assays, 10 l of overnight culture (2 ϫ 10 8 cells per ml) was spotted on Petri dishes containing 20 ml of solidified GM17 agar and allowed to grow overnight at 30°C. The resultant growth was killed by UV irradiation, and the plates
Results and Discussion

Identification of a dha Reductase LtnJ Responsible for the Second
Step of L-Serine to D-Alanine Conversion in Lacticin 3147. The genes responsible for production of and immunity to lacticin 3147 are encoded by two divergently transcribed operons (29) (Fig. 1) . The leftward four gene operon is involved in lacticin immunity and regulation, whereas five of the six genes of the larger operon have confirmed roles in lacticin biosynthesis and export (19) . No function has been assigned to the product of the remaining gene, ltnJ (previously designated orf40), located at the 3Ј end of the larger biosynthetic operon, prompting an investigation to determine whether the corresponding gene-product contributes to lacticin 3147 biosynthesis. Bioinformatic analysis revealed that LtnJ bears significant similarity to dehydrogenases͞reductases, in particular zinc-containing alcohol dehydrogenases and NAD(P)H-dependent quinone oxidoreductases of the zinccontaining alcohol dehydrogenase superfamily (Fig. 4 , which is published as supporting information on the PNAS web site). More specifically, LtnJ contains a stretch of amino acids that almost exactly matches the PROSITE accession no. PS00059 (available at http:͞͞au.expasy.org͞prosite) signature sequence for alcohol dehydrogenases (i.e., GHExxGxxxxx[G͞A]xx[I͞V͞ S͞A͞C] domain 2). The obvious discrepancy is that in LtnJ, like in quinone oxidoreductases, a serine replaces the conserved histidine, which in alcohol dehydrogenases is required for binding of a zinc atom essential for catalytic activity. LtnJ also differs from alcohol dehydrogenases in that it lacks other amino acids involved in the binding of catalytic and structural zinc atoms. However, LtnJ is also not a typical quinone oxidoreductase because it shows similarity to only part of PROSITE accession no. PS01162, the NAD(P)H-binding signature sequence for quinone oxidoreductases (i. To confirm this theory, we created a nonpolar deletion of ltnJ in pMRC01. The resultant ⌬ltnJ mutant does not inhibit the growth of the lacticin 3147-sensitive indicator L. lactis HP in well-diffusion assays, providing evidence that LtnJ plays a role in the biology of this inhibitor (Fig. 2) . This loss in bioactivity could be partially complemented through reintroduction of the ltnJ gene in trans on a separate plasmid, pNZ44. It was also notable from deferred antagonism assays that ⌬ltnJ retained some antimicrobial capacity that could be increased by the addition of native LtnA2 but not LtnA1 (Fig. 2) , indicating that deletion of ltnJ had a relatively greater impact on LtnA2 than LtnA1. This finding is supported by the diminished production of LtnA1 and A2 peptides, as evidenced by the HPLC profiles. The loss in production of LtnA2 was particularly striking, but sufficient peptide was present to generate a mass for both peptides. The analysis of the peptides purified from the ⌬ltnJ mutant revealed mass reductions of 2 and 4 mass units for LtnA1 and LtnA2, respectively. This difference in mass precisely corresponds to that expected as a consequence of the ''freezing'' of the two-step conversion of serine to dha to D-alanine in the intermediate step in both peptides. Thus, we propose that LtnJ plays the role of the second enzyme mooted by Skaugen et al. (13) and functions to stereospecifically convert the three remaining dha into D-alanines, a step that is obviously required for optimal lacticin 3147 bioactivity.
Quantitative RP-HPLC and relative activity assays (i.e., the activity of a peptide relative to an equal amount of its wild-type equivalent) were carried out to determine whether the reduced bioactivity associated to the presence of dha rather than Dalanine could be solely attributed to the observed reduction in peptide production or whether the relative activity of the peptides was also affected. For quantitative RP-HPLC lacticin peptides were purified from bacterial surfaces to minimize the presence of other hydrophobic peptides, a problem associated with purifications from culture supernatant. Purification by this means resulted in RP-HPLC profiles of high quality in which well separated peaks were visible. Production of LtnA1 was 5-fold lower from the ⌬ltnJ mutant, whereas LtnA2 production was minimal (Ͼ100-fold reduction) ( Fig. 2 and Table 1 ). The extremely low level of LtnA2 is consistent with the failure of LtnA1 to restore bioactivity to the ⌬ltnJ mutant. The presence of a dha rather than D-alanine in LtnA1 reduced the relative activity by 4-fold, suggesting that the overall loss in activity of LtnA1 is due to a combination of reductions in production (almost 5-fold) and relative activity (4-fold). Although these results show that Dalanines play a role in the bioactivity of such a peptide, unfortunately, it was not possible to recover sufficient LtnA2 from the mutant to facilitate relative activity studies.
Interestingly, in silico analysis revealed that three other genes located in bacteriocin operons or operons potentially associated with bacteriocin production are predicted to produce proteins showing high levels of homology to LtnJ. One such example, SacJ (previously designated Orf45), is 47.8% identical to LtnJ and is produced from an operon on the pETB plasmid of S. aureus (30) , which is associated with the production of the two-component lantibiotic staphylococcin C55. The lacticin 3147 and staphylococcin C55 lantibiotics are closely related, and every gene within the lacticin 3147 biosynthetic operon has a counterpart on pETB. The gene for another homolog, PenN (40.4% identity), is present on plasmid pMD136 (31) in Pediococcus pentosaceus. penN (orf022) is also present within an operon associated with production of a broad-spectrum bacteriocin, pediocin A. Because the pediocin A-encoding gene is not thought to be present on pMD136 (31) and the structure of the antimicrobial has not been determined, the nature of this bacteriocin is unknown. A final, more distantly related, homolog, which we designate NstJ (31.8% identical), is the predicted product of npun2849, a gene identified during shotgun sequencing of the cyanobacterium Nostoc punctiforme PCC73102 (GenBank accession no. NZAAAY02000000). Interestingly, despite the fact that, to date, lantibiotic production has only been associated with Gram-positive organisms, the adjacent gene in N. punctiforme, npun2848, is a homolog of ltnM1 and ltnM2. Although it is not known whether these three LtnJ homologs are functional or whether D-amino acids are present in peptides produced by these strains, their presence is intriguing. Although an LtnJ homolog has not been identified in the strain producing the D-alanine-containing lactocin S, it may be that such an enzyme is present and simply has yet to be found or that an unrelated enzyme performs this task. To determine to what extent the chirality of the D-alanines is important, each of the three relevant serine codons were systematically replaced with alanine codons. This alteration should precisely replace the D-isoform with the L-isoform, allowing us to determine whether it is the presence of an alanine or its chirality that is the primary reason for the dha to D-ala conversion. Because the presence of complex posttranslational modifications in lantibiotics restricts the creation of synthetic peptide analogues, alteration of the lacticin 3147 peptides was carried out within the producing strain. This goal was achieved by using site-directed mutagenesis combined with allelic exchange protocols developed in our laboratory (22) to incorporate changes into the native lacticin 3147-encoding plasmid, pMRC01. In all cases, the gene producing the unaltered companion peptide remained intact. Four such mutants were created: the single mutants A1-S7A, A2-S9A, and A2-S12A and the double mutant A2-S9,12A. With the exception of A2-S9A mutant, D-to L-alanine conversion of the lacticin peptides Fig. 2 . Bioactivity in an ltnJ knockout. Deletion of ltnJ results in a dramatic loss of activity (no zone in well-diffusion assays) against a sensitive indicator. Partial complementation can be achieved by heterologous expression of ltnJ in trans from pNZ44ltnJ. The loss in activity is primarily caused by reduced production of both peptides as indicated by the HPLC profiles (the profile from pMRC01 and pMRC01⌬ltnJ represent 10-and 20-ml eluates, respectively). Deferred antagonism assays confirm that pMRC01⌬ltnJ retains some inhibitory capacity observed as a zone of inhibition surrounding a colony. This activity can be enhanced by wild-type LtnA2 but not by LtnA1, confirming that the loss of LtnJ has a relatively greater impact on LtnA2. MS analyses confirmed the loss of 2 and 4 mass units from LtnA1 and LtnA2, respectively, from the ⌬ltnJ mutant. Impact of the replacement of D-alanines in LtnA1 and LtnA2 with respect to the relative bioactivity of culture supernatants (as determined by well-diffusion assay) and peptide production and relative activity of the engineered peptides. The relative activity of a peptide is the activity of that peptide relative to an equal concentration of the corresponding wild-type peptide (in the presence of unmutated companion peptide at a concentration below that required for independent inhibitory activity). nd, not determined; -, undetectable. Values in bold are associated with mutated peptides.
affected production, with A1-S7A production being most dramatically reduced to an extent that mitigated against relative activity determination (Table 1 ). In the case of LtnA2, the reduction in production was less dramatic, although relative activity determinations suggested that a single D to L conversion reduced activity by Ϸ4-fold and a double conversion resulted in a 16-fold loss in relative activity.
Interestingly, the D to L-alanine change in LtnA1 also resulted in a reduction in the amount of LtnA2 recovered. This result is almost certainly caused by the isolation procedure, which relies on desorption of the peptides, presumably from a receptor͞ immunity protein on the surface of the producer cell. Indeed, we have previously shown that binding to target cells is a two-step process mediated by LtnA1 (32) . Consequently, in the absence of LtnA1, LtnA2 is likely to be lost in the supernatant because it has no receptor peptide to facilitate binding. This theory was borne out by the fact that significant levels of LtnA2 are present in the corresponding supernatant (data not shown). Although nonproduction of A1-S7A also prevented determination of its mass, as expected, the masses of A2-S9A, A2-S12A, and A2-S9,12A were found to be identical to those of the unmutated peptides (Fig. 3) .
Incorporation of Codons for L-Threonine, Glycine, and L-Valine. To further investigate the significance of the chirality of the amino acid at the relevant positions in mature LtnA1 and LtnA2, we generated a number of mutants (A1-S7T, A1-S7G, A1-S7V, A2-S9T, A2-S9G, A2-S9V, A2-S9,12T, A2-S9,12G, and A2-S9,12V) in which the original L-serine codons were replaced with those for glycine, L-valine, and L-threonine. Introducing threonine for serine was of particular interest because it was theoretically possible that the residue could be converted to dhb by the relevant lanthionine synthetase or to D-aminobutyrate through the action of LtnJ. Mass determination of the LtnA1 peptides from A1-S7T, A2-S9T, and A2-S9,12T peptides confirmed that the threonines at all three locations were converted to dhb (a change of 12 mass units for each conversion; see Fig.  3 ). Thus, this data provides further evidence that the dehydration of hydroxyamino acids in lantibiotics is location-specific because LtnA2 possesses three unmodified threonines and because dhb does not act as a substrate for a subsequent LtnJcatalyzed reduction to D-aminobutyrate. Mass analysis of all glycine and valine mutants demonstrated that in each case where a mutant peptide was produced its mass was altered as anticipated (i.e., Ϫ12 and ϩ28 mass units for each glycine and valine incorporated, respectively; see Fig. 3 ).
Of all of the amino acids introduced L-valines consistently caused the most dramatic reductions in bioactivity. No production of A1-S7V could be detected, and the relative activity of the A2-S9V and A2S9,12V peptides was reduced to an even greater extent than the corresponding L-alanine mutants ( Fig. 3 and Table 1 ). Thus, amino acids with side chains in the L orientation do not act as effective substitutes for the D-alanines, and it would furthermore appear that the deleterious consequences of such replacements become more pronounced as the size of the side chain increases.
The consequences of replacing D-alanines with the nonchiral amino acids dhb and glycine were relatively less dramatic, and in all cases at least some bioactivity was retained (Table 1) . Of all amino acids incorporated dhb most effectively replaced the D-alanine in LtnA1, leading to a 50% reduction in both production and relative activity ( Fig. 3 and Table 1 ). Glycine was the most effective replacement for the D-alanines in LtnA2, with less effect on relative activity than any other amino acid incorporated. Taken together with the earlier results describing the impact of dha (⌬ltnJ) and L-alanine, these results demonstrate that the presence of side groups in the L orientation (alanine and valine) at the sites normally occupied by D-alanines in LtnA1 and LtnA2 is detrimental to production and relative activity, whereas nonchiral residues (dha, dhb, and glycine) are relatively more acceptable.
The results of this study are important for a number of reasons. First, a vital biological role for D-amino acids in ribosomally synthesized prokaryotic peptides has been confirmed. This study has far-reaching implications because assumptions used ubiquitously in (prokaryotic) biology, i.e., that the codon predicts the residue and that all residues are in the L-conformation, have been overturned in this instance. It is highly unlikely that these three L-serine to D-alanine conversions in lacticin 3147 (and a further three in lactosin S) are the only exceptions to this generally accepted rule, and we can expect that other examples will emerge as more peptides and proteins are subjected to a closer interrogation by MS, chiral phase analysis, and other equally exacting methodologies. However, the mechanistically distinct way in which D-amino acids would seem to be generated in lantibiotics suggests that D-amino acids generated in this way may be less common in nonlantibiotics. It is also important to note that this conversion is not simply a biological oddity but that it plays an important role in the production of fully active peptides.
The data generated gives an insight into the role of the D-alanine residues in LtnA1 and LtnA2. For LtnA1, the replacement of D-alanine most dramatically affects peptide production. This phenomenon has also been associated with a number of other engineered lantibiotics, especially those in which modified amino acids are altered (33) . It has been suggested that inhibition of the enzymes of the modification machinery may be the most likely explanation (34) . Although nonproduction of LtnA1(7A) and (7V) meant that it was not possible to determine to what extent a D to L conversion would affect the relative activity of LtnA1, it was apparent that significant levels of relative activity were retained upon the replacement of D-alanine with nonchiral amino acids.
Reduced production was also a feature of a number of LtnA2 derivatives, which was more apparent for double rather than single mutants. Whereas the wild-type peptide possessed the highest levels of relative activity, it was interesting to note that this was matched by the A2-S9G peptide. Although the chirality of the newly incorporated amino acids in the LtnA2 derivatives is significant, it also is interesting to note that the size of the newly incorporated amino acid would also seem to be a factor given that the relative activity of the glycine and L-alanine mutants are consistently greater than the equivalent dhb and L-valine derivatives, respectively. It may be that the smaller amino acids are less likely to interfere with the formation of the putative ␣-helix (A 7 -I 15 ) in LtnA2 (15) . These structures have been demonstrated to be of critical importance to the antimicrobial activities of many linear amphipathic antimicrobial peptides (35, 36) . The consequences of replacing D-alanines in lacticin 3147 are variable and depend on whether the alteration is to LtnA1 or LtnA2 and on the location within the peptide. Despite this variability, it is apparent that, as with many other antimicrobial peptides, be they natural or synthesized, the presence of D-amino acids in lacticin 3147 is essential for optimal bioactivity. Thus the identification, cloning, and expression of the enzyme responsible for the creation of a D-alanine from a dha intermediate in a lantibiotic is a significant development. From an even broader peptide chemistry perspective, this study represents the identification of an enzyme responsible for the introduction of D-amino acids in prokaryotic, ribosomally synthesized peptides and indicates that the formation of D-amino acids in lantibiotics is distinct from the mechanism responsible for the presence of such residues in -agatoxin IVb (3). Significantly, a recent study has shown that lantibiotic synthetases are capable of acting in vitro to introduce dehydroamino acids into ribosomally synthesized peptides (37) . The identification of LtnJ offers the very real prospect that we will be able to further convert these residues into D-isoforms, perhaps conferring additional functionality on biologically active peptides. Of course, it will be important to determine the specificity of LtnJ in terms of peptide sequence͞structure to examine the overall applicability of this approach to different protein͞peptide substrates. Until now, chemical synthesis has been the only way to create peptides and peptide libraries containing D-amino acids (usually done as a means to improve protease stability, alter tertiary structure, affect the activity of bioactive peptides, and remove the toxicity of cytolytic antibacterial peptides toward mammalian cells). The ability to create D-residues in a ribosomally synthesized peptide chain will open a new vista in enzyme biochemistry and may provide a more practical means of designing and creating D-amino acid-containing peptides͞proteins that may exhibit novel antimicrobial activities.
